Carnegie Mellon University »

Predictive Oncology shares owned by Carnegie Mellon University

Quarter-by-quarter ownership of Predictive Oncology (POAI) shares owned by Carnegie Mellon University from 13F filings

Historical chart of Carnegie Mellon University investment in Predictive Oncology

Tip: Access up to 7 years of quarterly data

All positions including Predictive Oncology held by Carnegie Mellon University consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Predictive Oncology by Carnegie Mellon University

Quarter filed Position value Share count Share price at filing
2023-12-31 $34k 10k 3.29

More positions owned by Carnegie Mellon University

Duolingo Cl A Com (DUOL)
Carmell Therapeutics Corp - US (CTCX)
Vera Therapeutics Cl A (VERA)
Neubase Therapeutics Com New (NBSE)
Predictive Oncology (POAI)
Innsuites Hospitality Trust Sh Ben Int (IHT)

View all positions for Carnegie Mellon University

Top funds holding Predictive Oncology

Vanguard Group
Raymond James & Associates
RB Capital Management
Carnegie Mellon University
UBS Group
Advisor Group Holdings
PSI Advisors
Wells Fargo & Company
Jpmorgan Chase & Co
Bank of America Corporation
PFS Partners

View all funds holding Predictive Oncology